What does the PREVENT trial tell us about managing vulnerable plaques? Recorded during #europcr 2025, this discussion features Michael Haude and Thomas Cuisset as they review key insights from this major study of over 1,600 patients with physiologically non-significant but vulnerable plaques identified by intracoronary imaging—mainly IVUS. Patients were randomised to receive either optimal medical therapy (OMT) alone or combined with preventive PCI, and followed over several years. While the composite endpoint favored the PCI group, the benefit was driven solely by a reduction in target lesion revascularisation—without differences in death or myocardial infarction. Should PCI be systematically performed in such cases? Tune in for a nuanced expert perspective! Hosted on Acast. See acast.com/privacy for more information.

Ver todos los episodios